Army VEDDER Biotech Accelerator, Cohort 1
Status: Open. Applications close October 30, 2026, 11:59 p.m. Eastern. Two challenges: VTCS-01 small-molecule CBRN countermeasure design and VTCS-02 low-SWaP edge-AI sensing.
Executive summary
VEDDER is a U.S. Army biotechnology accelerator run by the nonprofit D!NG under an Other Transaction agreement. Cohort 1 seeks U.S. companies for small-molecule CBRN countermeasure design and edge-AI distributed sensing. Applications close October 30, 2026 at 11:59 p.m. Eastern; late submissions are not accepted.
Selected companies sign a milestone-based prototype agreement with D!NG, with payment tied to demonstrated progress. It is not a grant, and companies keep ownership of their technology subject to negotiated data rights.
Solicitation at a glance
- Agency: U.S. Army, through the Defense Innovation Networking Group (D!NG), a 501(c)(3) nonprofit
- Opportunity: VEDDER Biotechnology Accelerator, Cohort 1
- Challenges: VTCS-01 Rapid Small-Molecule Design for CBRN Medical Countermeasures; VTCS-02 Low-SWaP Distributed Sensing with On-Device Edge AI
- Award vehicle: Milestone-based prototype agreements; D!NG operates under a federal Other Transaction agreement
- Funding: Not yet posted on the challenge page
- Technology maturity: Demonstrable technology, not a concept, with a self-rated TRL
- Due date: October 30, 2026, 11:59 p.m. Eastern (intake opened October 12, 2026)
Think your company qualifies? Talk with BW&CO before the October 30 deadline.
What is VEDDER?
VEDDER is a biotechnology accelerator for U.S. companies whose technology serves both commercial markets and national security needs. It connects selected companies with technical resources, business support, capital networks and government acquisition expertise.
What problem is the Army trying to solve?
The Army wants faster discovery of medical countermeasures for chemical and biological threats, and small, low-power sensors that report useful information about chemical, biological and environmental signals without relying on heavy infrastructure.
Priority capability areas: what VEDDER is looking for
- VTCS-01: target identification and validation, de novo small-molecule design, multi-attribute optimization (ADMET, PK/PD, safety, scalability), in-silico characterization, and cell-based demonstration against a known target
- VTCS-01 out of scope: diagnostics, radiopharmaceuticals, repurposing approved drugs, biologics-only platforms, late-stage clinical programs
- VTCS-02: miniaturized chemical, biological and environmental sensing, on-device inference and anomaly detection, low-power networking, ruggedization and manufacturability
- VTCS-02 out of scope: cloud-dependent architectures, laboratory bench instruments, sensing with no path to field deployment
Eligibility
- Ownership: organized in the U.S. and majority U.S.-owned and controlled
- Foreign investment: must be disclosed; foreign ownership or influence may disqualify
- Personnel: key personnel must be U.S. citizens and assigned personnel must meet security requirements
- Technology: demonstrable, with a self-rated TRL
- Business: commercially viable with or without government customers, and willing to team where a challenge calls for it
- Who can apply: startups, small businesses, university spin-outs and nontraditional defense contractors are welcome; no prior government contracting experience is required
How to apply
- Pass the short eligibility screen on the D!NG VEDDER application page.
- Answer the 10 challenge questions and self-rate your TRL.
- Upload a 1 to 2 page capability statement in any format.
- Submit one application per challenge by October 30, 2026, 11:59 p.m. Eastern.
What happens after you submit?
- Mid-November 2026: selected applicants invited to propose
- December 2026 to January 2027: selections and agreements expected
Is this opportunity a good fit for your company?
It fits a U.S. company with a working AI-driven small-molecule discovery platform or an edge-AI chemical and biological sensor, plus a commercial market of its own. It does not fit early concepts, biologics-only platforms, cloud-only sensing or companies with significant foreign ownership.
How BW&CO can help
BW&CO has helped deep-tech and dual-use founders secure more than $350M in non-dilutive funding. For accelerators and prototype agreements like VEDDER, we help you:
- Check eligibility and foreign-investment questions early
- Pick the challenge that matches your technology
- Answer the 10 questions with evidence, not adjectives
- Write a tight capability statement
- Prepare for the invited proposal and milestone plan
Frequently asked questions
Who runs VEDDER?
The Defense Innovation Networking Group (D!NG), a 501(c)(3) nonprofit, operates VEDDER for the U.S. Army under a federal Other Transaction agreement.
When do applications close?
October 30, 2026 at 11:59 p.m. Eastern. Late submissions are not accepted.
How much funding is available?
The challenge page says awards are milestone-based prototype agreements and that the indicative range for Cohort 1 will be published at intake. No range was posted on the page when this summary was written.
Is this a grant?
No. It is a milestone-based prototype agreement, with payment tied to demonstrated progress.
Do I keep my intellectual property?
Companies keep ownership of their technology, subject to negotiated data rights.
Can a company with foreign investors apply?
Companies must be majority U.S.-owned and controlled and must disclose all foreign investment. Foreign ownership or influence may be disqualifying.
Can I apply to both challenges?
You may submit one application per challenge.
What does the application include?
An eligibility screen, 10 challenge questions with a TRL self-rating, and a 1 to 2 page capability statement.
Can BW&CO help with a VEDDER application?
Yes. We help teams check eligibility, choose the right challenge and write clear answers and a capability statement. Book a call with our team.
The deadline for this opportunity has passed. Find open opportunities in our Non-Dilutive Funding Opportunities Database.